Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26910574 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2BRD4KMT2AMEN1PKM | |
| SCHEMBL26099322 | 0.88 | LMNA (0.40) | SMN1; SMN2BRD4KMT2AMEN1PKM | |
| SCHEMBL26100676 | 0.88 | LMNA (0.40) | SMN1; SMN2BRD4KMT2AMEN1PKM | |
| SCHEMBL26910518 | 0.85 | FAAH (0.33) | ALDH1A1 | |
| SCHEMBL26910522 | 0.85 | FAAH (0.33) | ALDH1A1 | |
| SCHEMBL26097698 | 0.82 | NPC1 (0.40) | SMN1; SMN2KMT2AMEN1PKMLMNA | |
| SCHEMBL26098035 | 0.82 | NPC1 (0.40) | SMN1; SMN2KMT2AMEN1PKMLMNA | |
| SCHEMBL26532480 | 0.82 | NPC1 (0.40) | SMN1; SMN2KMT2AMEN1PKMLMNA | |
| SCHEMBL26098238 | 0.79 | LOX (0.37) | SMN1; SMN2TDP1 | |
| SCHEMBL26098242 | 0.79 | LOX (0.37) | SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | ANOVIA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | SMN1; SMN2 3180/4885BRD4 1577/4885KMT2A 1260/4885 |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | LOX, LOXL1, LOXL2 | SMN1; SMN2 1926/4885BRD4 3244/4885KMT2A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.